Respiratory Support in Severe Chronic Obstructive Pulmonary Disease Exacerbation

• Conditions: COPD Exacerbation

• Registration Number: NCT03020394
• Lead Sponsor: China-Japan Friendship Hospital

Brief Summary

Preliminary studies have shown that NPPV can avoid tracheal intubation in 40% to 60% patients who have severe exacerbation of COPD. Recently, large-scale comparative effectiveness research (CER) also found that compared with invasive ventilation, NPPV can reduce mortality rates. But there's no high-quality clinical studies which can confirm this. Therefore, investigators believe that NPPV can avoid intubation in patients with severe exacerbation of COPD in ICU with perfect monitoring conditions and reasonable human resource allocation, in order to reduce IMV-related complications and improve patients' outcomes.

Detailed Description

In part of the patients who were AECOPD with pH \<7.25 , preliminary studies have shown that NPPV can avoid tracheal intubation in 40% to 60% patients, and also reduce the incidence of VAP. Recently, large-scale comparative effectiveness research (CER) also found that compared with invasive ventilation, NPPV can reduce mortality rates. At present, there's no high-quality clinical studies which can confirm this, and clinical guidelines do not have a recommendation on the use of NPPV in these patients. Therefore, investigators believe that NPPV can avoid intubation in patients with severe exacerbation of COPD in ICU with perfect monitoring conditions and reasonable human resource allocation, as well as the progress of medical technology in NPPV in recent years, in order to reduce IMV-related complications and improve patients' outcomes.

Study Timeline

• Study Start: 2017-01
• Study First Submitted: 2017-01-09
• Study First Submitted QC: 2017-01-11
• Study First Posted: 2017-01-13
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-13
• Last Update Posted: 2020-01-18
• Primary Completion: 2020-12
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 208

Inclusion Criteria

• AECOPD;

Exclusion Criteria

• refuse to engage in the study;
• have been included in other study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The incidence of ventilator-associated pneumonia (VAP)	90days
The all cause mortality of ICU and hospitalization	90 days

Secondary Outcome Measures

Name	Time	Method
The length of stay of ICU and hospitalization	90 days
The length of stay of mechanical ventilation	90 days

Trial Locations

Locations (1)

China-Japan Friendship hospital; 🇨🇳 Beijing, Beijing, China